ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Cleveland BioLabs Inks Pact With Russia

by Rick Mullin
August 6, 2012 | APPEARED IN VOLUME 90, ISSUE 32

Cleveland BioLabs has signed a $4 million agreement with the Russian Ministry of Industry & Trade for CBLB612, a drug in development for stimulation of hematopoietic stem cell proliferation and mobilization. The contract, issued under Russia’s Pharma 2020 initiative, provides funding over a three-year period to support research through Phase II clinical trials. Cleveland BioLabs says CBLB612 is a candidate for use in bone marrow transplants.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment